insitro is a biotechnology company that applies causal AI and machine learning to drug discovery, with a focus on neuroscience and metabolic diseases. The firm integrates multi-modal human and cellular data to understand disease mechanisms and design therapeutics. Its technical work spans causal AI, multi-modal data integration, machine learning, genomics, and drug discovery.
The company has built what it describes as the world's largest integrated multi-modal corpus of human and cellular data. Two key platforms underpin its approach: Virtual Human™, a genetically anchored causal AI engine designed to reveal how disease begins, progresses, and can be resolved; and TherML™, an AI platform used to identify causal genetic drivers and design optimal medicines.
insitro operates at the intersection of the pharmaceuticals and biotechnology industries. The company emphasises a collaborative culture that brings together life scientists, data scientists, engineers, and drug hunters, with a shared focus on identifying important questions, designing experiments, and generating scientific breakthroughs.
